News

Weekly Policy Update: Full Repeal of the Medical Device Tax Advocacy

Friday, July 20, 2018

This has been another week with persistent advocacy for full repeal of the Medical device tax in standalone legislation. A permanent repeal of the medical device excise tax remains a top priority for CBSA and Colorado's medtech innovators. While we are appreciative of temporary relief through the two- year suspension as part of the Continuing Resolution to fund the federal government, that abatement is set to expire on December 31, 2019.  

Weekly Policy Update: Medical Device Tax Advocacy and the CACI Legislative Candidate Interviews

Friday, July 13, 2018

CBSA continues to advocate for a full repeal of the Medical device tax in standalone legislation. A permanent repeal of the tax remains a top priority for CBSA and Colorado's medtech innovators. While we are appreciative for temporary relief through the two-suspension as part of the Continuing Resolution to fund the federal government, the suspension is set to expire on December 31, 2019. 
 

Weekly Policy Update: Meeting with Congresswoman Degette

Friday, July 06, 2018

This week Colorado BioScience Association along with AdvaMed, our Board Chair Scott Larson at Terumo BCT, Zimmer Biomet and ResMed met with Congresswoman DeGette. The meeting offered a great opportunity to talk about the importance of our industry and the exciting innovations taking place, as well as barriers presenting current challenges.  

Weekly Policy Update: Primary Elections, Congratulating Sen. Gardner, and Drug Pricing

Thursday, June 28, 2018

2018 COLORADO PRIMARY ELECTION
 
Continue Reading

Weekly Policy Update: FDA Releases Important Guidances

Thursday, June 21, 2018

The FDA recently announced the release of important guidances, “Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities–Questions and Answers,” and “Medical Product Communications That Are Consistent With the FDA-Required Labeling”. The first guidance answers common questions about companies’ communications to payors, including insurance companies, formulary committees and similar entities. The second guidance provides the FDA’s views on manufacturers’ communication of information that is not contained in the FDA-required labeling for their products, but that is consistent with that labeling. Both guidances are critical to outline how companies can communicate off-label health care economic information about their products to health plans, hospitals and other drug purchasers.  

Weekly Policy Update: Drug Pricing News

Friday, June 15, 2018

This week HHS Secretary Alex Azar appeared in front of the Senate Health, Education, Labor and Pensions Committee for a hearing on drug pricing. Secretary Azar’s prepared testimony in large part summarized President Trump’s blue print. For more information on the blueprint click here and to view the full hearing click here
 

Weekly Policy Update: BIO International Convention

Friday, June 08, 2018

This week CBSA President and CEO April Giles and Vice President Jennifer Jones returned from the 2018 BIO International Convention in Boston, Massachusetts. This annual trip is a great opportunity to meet with CBSA member companies, industry partners, and other bioscience supporters. The convention also provides a venue where we can learn directly from industry leaders and share policy lessons, trends and insights.  

Weekly Policy Update: The Colorado Experience, Tariff Advocacy, and FDA Funding News

Friday, May 25, 2018

COLORADO EXPERIENCE – BOULDER

 
Continue Reading

Weekly Policy Update: A Quick Review of President Trump’s Prescription Medication Plan

Friday, May 18, 2018


 

Weekly Policy Update: The Close of the Second Regular Session and Unveiling Federal Drug Price Policies

Friday, May 11, 2018